Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Colorectal Neoplasms × ascrinvacumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3 Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Camurati-Engelmann Syndrome 1 Advanced Solid Tumors 1

Interventions

Fluorouracil 447 Bevacizumab 422 Oxaliplatin 398 Leucovorin 393 Irinotecan 364 Capecitabine 279 Cetuximab 278 pembrolizumab 129 Folfox protocol 118 Panitumumab 100 regorafenib 95 Colonoscopy 76 IFL protocol 73 Nivolumab 70 Drug Therapy 69 trifluridine tipiracil drug combination 62 Radiotherapy 60 HMPL-013 53 Blood Specimen Collection 52 Neoadjuvant Therapy 43 Gemcitabine 43 Specimen Handling 40 Chemotherapy, Adjuvant 39 Biopsy 38 Standard of Care 37 Cyclophosphamide 37 Magnetic Resonance Spectroscopy 36 Surveys and Questionnaires 35 atezolizumab 34 Cisplatin 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02116894 2019-03-14

REGAL-1

Duke University

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡